Partner Sessions

CORPORATE PROGRAM

Explore the Corporate Program

Step into discussions on the technologies and strategies shaping the future of cell and gene therapy.

Led by industry leaders, these sessions explore emerging platforms, evolving development approaches, and innovations advancing clinical translation and commercialization. Hear how organizations across the CGT ecosystem are addressing key challenges in manufacturing, scalability, regulatory pathways, and patient access.

Please note: Presentation content and speakers are developed and selected by the hosting organization.

For the complete  ISCT Asia 2026 Scientific Program schedule with all sessions and events, visit the FULL PROGRAM .

  CORPORATE SESSIONS 

Speakers

  • Peiqing Zhang, Scientific Director, Genomic Medicine, Cytiva, Singapore
  • Alan K. Smith, PhD, Global Head of Innovation, Cell and Gene Therapy, Rose BioSolutions, Inc.
  • Martin Rabel, Service Solution Specialist, Cytiva, Germany

Presentation Abstract

CAR-T is moving fast and the next wave will demand more than one winning formula. This session brings together two powerful frontiers shaping the future of CAR-T: flexible ex vivo manufacturing and in vivo T cell reprogramming.
The ex vivo talk will share real-world experience with the Sefia™ manufacturing platform, highlighting how flexible, modular manufacturing can support diverse CAR-T workflows beyond fixed, fully integrated systems.
The in vivo talk will spotlight targeted LNP technology as a non-viral path to CAR-T, shifting CAR-T manufacturing inside the body. A case study will show how targeted LNPs can drive precise and potent T cell reprogramming in vivo, offering a potential route to overcome some of the toughest barriers of ex vivo CAR-T: complexity, time, scale, and access.
Join us for a practical, forward-looking discussion on how to build CAR-T strategies that are adaptable, scalable, and future-ready across ex vivo and in vivo frontiers.

Session Objectives

  • See where CAR-T is heading next across flexible ex vivo manufacturing and in vivo reprogramming.
  • Learn how modular platforms can unlock workflow flexibility beyond fixed, fully integrated systems.
  • Explore targeted LNPs as a non-viral route to in vivo CAR-T, shifting cell engineering inside the body.
View Website

Speakers

  • Speaker Details Forthcoming

Presentation Abstract

Session Details Forthcoming

View Website

Speakers

  • Dr. Ulf Bethke, Executive Expert Cell and Gene Therapy Asia Pacific, Miltenyi Biotec B.V. & Co.KG, Germany
  • Dr. Ledio Bocova, Global Product Manager CliniMACS Systems, Miltenyi Biotec B.V. & Co.KG, Germany

Presentation Abstract

As cell and gene therapy continues to evolve, there is an increasing need for integrated solutions that support efficient, standardized, and GMP-compliant manufacturing. This symposium will highlight two key aspects of advancing clinical cell therapy manufacturing.

The first session introduces the next-generation CliniMACS® Plus instrument, showcasing its enhanced versatility, intuitive user interface, and seamless GMP compliance to support reliable clinical-scale cell separation workflows.

The second session shares Miltenyi's practical experience in designing standardized, modular GMP facilities for autologous CAR-T cell therapy manufacturing. Through real-world case studies, attendees will gain insights into facility planning, scalability, implementation timelines, and regulatory considerations.

Together, these sessions demonstrate how innovations in cell processing technologies and manufacturing infrastructure can help accelerate the translation of advanced therapies from development to clinical practice.

Session Objectives

  • Explore the latest advancements in clinical cell separation technologies and their role in enabling standardized, GMP-compliant cell therapy manufacturing.
  • Understand practical approaches to designing and implementing standardized, modular GMP facilities for autologous CAR-T cell therapy manufacturing.
  • Gain insights into scalable manufacturing strategies that improve operational efficiency, reproducibility, and regulatory readiness for clinical cell therapy applications.
View Website

Speakers

  • Ted Tish, Vice President & General Manager, Cell Biology and Advanced Therapies (CBAT), Thermo Fisher Scientific, USA
  • Evan R. Zynda, PhD, Senior Innovation Lead, Cell Therapy R&D, Thermo Fisher Scientific, USA

Session Description

This session introduces next-generation technologies and process innovations that support allogeneic cell therapy manufacturing—from engineered T-cell therapies to iPSC-derived regenerative medicines.

Discover how the new Gibco™ CTS™ DynaXS™ single-use bioreactor platform, featuring flexible operating parameters and an automation-ready architecture, enables controlled, cGMP-ready T-cell expansion and scale-up. Downstream, learn how the Gibco™ CTS™ Compleo™ Fill and Finish System automates formulation and fill-finish operations in a functionally closed workflow. Through protocol-driven execution, automated calculations, in-process checks, and flexible batch-size handling, the CTS Compleo system helps improve consistency and quality in final drug product preparation for engineered cell therapies, including CAR-T, CAR-NK, and iPSC-derivatives.

The session concludes with a real-world case study from BetaLife, demonstrating how integrated manufacturing solutions support scalable production of iPSC-derived pancreatic islet cell therapies for insulin-dependent diabetes. Leveraging a proprietary 3D suspension manufacturing process and advanced genome engineering to insert multiple transgenes at safe harbour loci, BetaLife is advancing off-the-shelf allogeneic islet replacement therapies without long-term immunosuppression, with the potential to broaden patient access to a transformative treatment for diabetes.

Session Objectives

  • The Gibco Cell Therapy System (CTS) portfolio of products are cGMP manufactured, safety tested, and backed by regulatory documentation.
  • Learn how to streamline, integrate and scale manufacturing workflows with closed modular instruments, from cell expansion to fill-finish
  • Identify and harness key process control and flexibility benefits for therapy process development while maintaining scalability across diverse cell types
  • Discover real-world case study of how integrated workflow technologies can accelerate the translation of innovative regenerative therapies
View Website

Speakers

  • Patrick Carney, Ph.D., Nanotein Technologies
  • Rukmini Ladi, Sartorius
  • Paul Cashen, Sartorius

Session Description

Immune cell therapies such as CAR-T hold tremendous promise for previously incurable diseases; however, their broader clinical impact is limited by manufacturing and analytical challenges. Producing T cells at scale while maintaining viability, potency, resistance to exhaustion and long-term persistence remain constant hurdles. This is further compounded by the need for robust assays to consistently measure identity, purity and functional activity across batches. At the same time, CAR-T therapies depend on the supply of high-quality lentiviral vectors, where yield and efficient downstream purification are persistent bottlenecks.
 
This session will present integrated strategies to overcome these challenges, including the use of novel next-generation immune cell activators, the development of scalable manufacturing processes using stirred-tank bioreactors and DOE-driven process optimization, and advanced analytical approaches such as high-throughput live-cell imaging and cytometry. In addition, key aspects of lentiviral vector purification, such as chromatography and tangential flow filtration, will be discussed. Together, these approaches aim to enable more efficient, reproducible, and accessible manufacturing of immune cell therapies.  

Session Objectives

• Assess how next-generation soluble immune cell activators can generate more potent immune cells while simplifying workflows and eliminating the need for beads.
 
• Examine a case study demonstrating how stirred-tank bioreactors and Design of Experiments (DOE) methodologies were used to identify critical process parameters and develop scalable manufacturing processes while preserving cell functionality.
 
• Explore integrated analytical and downstream solutions, including live-cell imaging with high-throughput cytometry for rapid product characterization and scalable lentiviral vector purification strategies to increase process yield of infectious lentiviral vector. 
View Website

Speakers

  • Dr. Wenyan Leong, Director, APAC Commercial and Global Strategic Partnerships, Cell and Gene Therapies
  • Cyrus Yang, CEO, Taiwan Bio Therapeutics Inc., Taiwan
  • Sharon Sagnella, Clinical Cell Therapies Processing Facility Director | Royal Prince Alfred Hospital, Director of Research & Development, Australia

Session Description

This 60-minute roundtable panel discussion will bring together cell and gene therapy leaders from across Asia to explore the practical manufacturing challenges that emerge as CGT programs move from early innovation toward clinical implementation. While scientific progress continues to accelerate, many therapy developers still face difficult questions around process complexity, scalability, cost, consistency, automation adoption, and operational readiness.

The discussion will examine whether these challenges differ in Asia compared with the US and Europe, and what makes the regional context unique. Panelists will share perspectives on where automation and closed-system processing can create the greatest value, how the industry can improve standardization while preserving manufacturing flexibility, and what ecosystem support is needed beyond equipment alone.

By connecting clinical, technical, and operational viewpoints, the session aims to provide practical insights for hospitals, biotech companies, and manufacturing teams seeking to build more reliable, scalable, and accessible CGT manufacturing workflows across Asia.

Session Objectives

  • Identify key manufacturing challenges as CGT programs move toward clinical implementation.
  • Discuss what makes CGT manufacturing in Asia unique.
  • Explore how automation and closed systems can improve reliability and scalability.
  • Understand the support needed to enable practical adoption beyond equipment alone.
View Website

Speakers

  • Joshua Ooi, Ph.D., Associate Professor, Head of Regulatory T cell Therapies Group, Monash University, Australia
  • Leon Brownrigg, PhD., Senior Medical Scientist, Cell and Tissue Therapies (CTTWA), Royal Perth Hospital, Australia 

Session Description

The next wave of cell therapies will depend not only on breakthrough biology, but also on manufacturing strategies that enable safe, scalable and accessible clinical translation. This session brings together leading clinical and translational researchers to discuss how strategic partnerships are accelerating the development of next-generation Treg and TIL therapies. 

Our invited experts will explore emerging approaches including TCR-engineered antigen-specific Tregs for autoimmune disease, clinically applicable suppressor T-cell platforms for transplantation, and point-of-care manufacturing of autologous TIL therapies for advanced melanoma. Drawing on real-world clinical and manufacturing experience, they will share lessons from developing robust, cost-effective and clinically deployable workflows, including the integration of advanced cell processing technologies to support manufacturing consistency and scalability.

Through collaborations spanning academia, hospitals and industry, the discussion will highlight how scientific innovation, process development and enabling technologies are converging to overcome translational bottlenecks and accelerate the path from discovery to clinical impact for next-generation cell therapies. 

Session Objectives

  • Discover how strategic partnerships can accelerate cell therapy commercialization
  • Gain valuable insights on building effective research-industry collaborations to overcome manufacturing and translational challenges
  • Explore how closed, modular Cell Therapy Systems (CTS) solutions support scalable manufacturing and clinical translation of Treg and TIL therapies.
View Website
  COMPANY PRESENTATIONS 

Speakers

  • Matthew Hewitt, VP, CTO Manufacturing Business Division, Charles River, USA

Session Description

The manufacturing processes of innovative cell and gene therapy products have no or only limited viral clearance capacities. Therefore, virus safety testing is key for the used starting materials and raw materials to prevent that viral contaminants are introduced into the manufacturing process. In addition to or as an alternative to traditional viral detection methods, next-generation sequencing (NGS) can be utilized for the detection of viral contaminants.

Session Objectives

  • Viral contamination risk mitigation strategy for biologics
  • Viral contamination risk mitigation strategy for CGT
  • Traditional adventitious virus detection methods & limitations
  • Virus detection by NGS
  • Adventitious agent test strategy for HEK293 cells
  • Replication competent viral vectors
View Website

Speakers

  • Sean Chang, CEO, Locus Cell Co., Ltd., Taiwan

Session Description

This session explores how regenerative medicine products move from clinical development to manufacturing readiness, and how Taiwan is emerging as a key hub within Asia's regenerative medicine ecosystem. Through insights from advanced therapy manufacturing and a regenerative ophthalmology case study involving collaboration between Taiwan and Australia, attendees will learn how clinical, regulatory, and manufacturing capabilities can be integrated to accelerate the development and delivery of regenerative medicine products.

Session Objectives

  • Explore the role of CDMO infrastructure, quality systems, and digital manufacturing in advanced therapy development.
  • Learn how Taiwan is building integrated capabilities across clinical, regulatory, and manufacturing domains to support regenerative medicine.
  • Examine how cross-border partnerships can accelerate the development and commercialization of regenerative medicine products.
View Website

Speakers

  • Marco Pupo, PhD, Innovation and Development Coordinator, Italy

Session Description

Anemocyte is a leading Italian Biotech Manufacturing Organization (BMO) with extensive experience in the field of Cell and Gene Therapies (CGTs) and nucleic acid research, development and manufacturing.
 
Anemocyte’s core capabilities lie in two specific areas of expertise:
  • pDNA (Plasmid DNA); 
  • mRNA (messenger RNA).
The company leverages over twenty five years of experience to address the continuously evolving needs of the advanced therapies market.
A key innovation differentiating Anemocyte is its proprietary, patent-pending technology, AMCAP™.
AMCAP™ is a game-changing one-pot technology for mRNA synthesis that intelligently merges the crucial steps of transcription and capping into a single, seamless reaction resulting in different key advantages such as increase in efficacy and speed, cost-effectiveness, flexibility and scalability.
AMCAP™ enables the rapid synthesis of high-performance mRNA, positioning Anemocyte at the forefront of the enzymatic capping evolution in mRNA manufacturing.

Session Objectives

  • pDNA and mRNA development and manufacturing solutions 
  • custom and Off the Shelf products
  • innovative capping technology: AMCAPTM
  • analytical services for pDNA and mRNA needs
View Website

Speakers

  • Coming Soon

Session Description

Coming Soon
View Website

Speakers

  • Akihiro Okano, Pharmacist, MBA, Business Development Manager, TEIJIN REGENET CO., LTD., Japan

Session Description

Teijin Regenet Co., Ltd. is a CDMO providing contract development and manufacturing services for cell therapy and regenerative medicine products. Through its Kashiwa-no-ha Facility and Iwakuni Factory, Teijin Regenet offers flexible support tailored to each stage of development, from products for clinical research and clinical trials to commercial manufacturing.

This presentation will introduce Teijin Regenet’s capabilities, including the quality and production technologies cultivated by the Teijin Group in the pharmaceutical and medical device fields, as well as practical know-how in the commercialization of regenerative medicine products through collaboration with J-TEC. The presentation will also highlight Teijin Regenet’s experience with various cell therapy modalities, including CAR-T cells, MSCs, and iPS cells.

In addition, the session will describe how Teijin Regenet supports academia, startups, and biotech companies from research and development through commercialization, market launch, and stable supply, leveraging the Kashiwa-no-ha regenerative medicine platform and partnerships in Japan and overseas.

Session Objectives

  • Understand the value Teijin Regenet provides as a regenerative medicine CDMO.
  • Learn about Teijin Regenet’s support framework from early-stage development to commercial manufacturing of cell therapy and regenerative medicine products.
  • Understand the roles and features of the Kashiwa-no-ha Facility and Iwakuni Factory. 
  • Gain insight into Teijin Regenet’s manufacturing, quality, and regulatory capabilities for modalities such as CAR-T cells, MSCs, and iPS cells.
  • Understand how startups and biotech companies can leverage CDMO support to advance commercialization.
  • Explore the potential of regenerative medicine development support networks in Japan and the Marc-Aurele Brun APAC region.
View Website

Speakers

  • Marc-Aurele Brun, Sony Corporation, Japan

Session Description

After a quick review of the CGX10 Cell Isolation System key features, we will present some use cases of integration into closed workflows for the manufacturing of next generation cell therapies, e.g. CAR-T, Treg, TIL, iPSC based cell therapies.

These will highlight the flexibility of CGX10 to adapt to a variety of innovative cell therapies and requirements thereof such as speed, purity or recovery. Some examples of closed workflow integration with up/downstream processing solutions will also be discussed.

Session Objectives

  • Rationale for multiparameter selection
  • Type of next generation cell therapies enabled by CGX10
  • Key features of CGX10
  • Key considerations for the integration of CGX10 in a manufacturing workflow: adjustment to critical quality attributes requirements and up/downstream processing solutions
View Website

Speakers

  • Dr. Felix Dobbs, Broken String Biosciences (COO), UK

Session Description

Advances in genome editing are enabling cell and gene therapies that offer curative treatment for many diseases. However, unintended off-target DNA breaks remain a key safety concern, as they can drive genomic instability and malignant transformation in edited cells. Comprehensive genome-wide characterisation of on- and off-target breaks is therefore critical across discovery and preclinical development. This need is reinforced by the FDA's April 2026 draft guidance, which recommends NGS-based methods for evaluating off-target editing risk and loss of genome integrity in support of IND applications.

Despite this, sensitive, unbiased methods for therapeutically relevant cells have been limited, relying on indirect readouts, distorted by PCR amplification bias, and an inability to distinguish editing-induced breaks from background damage. These constraints make off-target data difficult to interpret, standardise, and scale.
INDUCE-seq® is a scalable, genome-wide, cell-based platform addressing these limitations through direct, PCR-free mapping of editing-induced DNA breaks, using a novel in situ break-labelling approach coupled with next-generation sequencing. It delivers a sensitive, unbiased, single-nucleotide-resolution readout that characterises on- and off-target sites simultaneously.

This talk presents data linking editing-induced breaks to downstream mutational outcomes, showing why direct detection is essential for safety assessment. We also demonstrate broad applicability across cell types, nuclease systems, and base editing modalities within one standardised workflow.

Session Objectives

  • Why direct break detection matters: editing-induced DNA breaks link to downstream mutational outcomes, making direct DSB detection essential for safety assessment. 
  • Why current methods fall short: indirect readouts, no therapeutic cell context, PCR bias, and an inability to separate editing-induced breaks from background damage. 
  • How INDUCE-seq® solves this: PCR-free, in situ break-labelling with NGS for a sensitive, unbiased, single-nucleotide-resolution readout of on- and off-target sites directly in any therapeutically relevant cell. 
  • One workflow, full landscape: works across cell types, nuclease systems, and base editing modalities. 
  • Regulatory alignment: INDUCE-seq supports the FDA's April 2026 draft guidance on NGS-based off-target assessment for IND applications.
View Website

Speakers

  • Coming Soon

Session Description

Coming Soon
View Website

Speakers

  • Dr. Daria Olijnyk-Dallis, Touchlight, USA

Session Description

Enzymatically produced circular DNA formats offer an alternative to conventional plasmids, allowing high sequence complexity, secondary structures, and elimination of bacterial or phage-derived sequences. These studies aimed to evaluate enzymatic circular DNA formats as flexible templates for gene editing and expression.
We evaluated mbDNA™, a circular single-stranded DNA containing a defined double-stranded stem loop, as a donor template for homology-directed repair (HDR) in immune and stem cell populations using an ex vivo CAR T-cell workflow. DNA from a GMP-representative manufacturing process was electroporated into cells, with knock-in efficiency, viability, proliferation, and functional phenotype assessed. mbDNA demonstrated minimal toxicity and achieved impressive 75% knock-in efficiency, while maintaining cell counts (similar to the DNA-free control) over a concentration range.
To extend applicability beyond HDR, additional custom circular DNA formats (sscDNA, hsscDNA, & dscDNA) incorporating user-defined single- and double-stranded regions were developed for compatibility with recombination, transposition, and homology-independent targeted integration (HITI) editing platforms.
Collectively, these data demonstrate that enzymatically produced circular DNA formats can support multiple gene editing and expression modalities while being compatible with a variety of delivery techniques such as electroporation and lipid nanoparticle (LNP) delivery, providing a flexible and scalable DNA payload platform for cell and gene therapies.

Session Objectives

  • Enzymatically produced circular DNA formats provide a scalable, non-viral alternative to plasmids for delivering large and complex gene editing payloads.
  • mbDNA™ achieves ~75% HDR knock-in efficiency in CAR T-cell workflows, ~40% in CD34+ HSCs with 10-15x better engraftment in vivo
  • Additional engineered DNA formats (sscDNA, hsscDNA, dscDNA) expand compatibility beyond HDR to recombination, transposition, and HITI-based editing
  • The platform is compatible with multiple delivery methods, including electroporation and lipid nanoparticles (LNPs)
View Website

Speakers

  • XL Lin, Founder, CEO, Esco Aster Pte Ltd, Singapore

Session Description

3D single use fixed packed bed bioreactors are widely used for commercial manufacture of biologics, including viral vectors, oncolytic viruses, secretomes, extracellular vesicles and exosomes. However, there is limited adoption for therapies where the final product is harvested cells. This is due to challenges associated with seed train expansion, which is generally less efficient than microcarrier-based suspension culture with tank-to-tank microcarrier transfer, as well as the complexities of downstream cell harvesting and processing.

We present the use of 3D Tide Motion packed-bed bioreactor technology for whole-cell manufacturing. Human induced pluripotent stem cells (iPSCs) were successfully cultured in the 50 mL MiniTide® bioreactor. Mesenchymal stromal cells (MSCs) were expanded in 0.1 L bioreactor for ~1 billion cells. The process is integrated with an automated closed-system single use cell harvester and downstream processing workflow, addressing one of the key historical limitations of fixed-bed bioreactors for stem cell therapy manufacturing.

This breakthrough has the potential to significantly reduce (COGs) compared with multilayer cell culture systems, providing a scalable, closed, and automated manufacturing platform for allogeneic cell therapies. Such technology is particularly timely given the recent U.S. FDA approval of allogeneic MSCs for GVHD, which are expected to drive demand for other MSCs therapies.

Session Objectives

  • Fixed-bed bioreactors are well established for manufacturing secreted biologics such as viral vectors, oncolytic viruses, secretomes, and extracellular vesicles (EVs/exosomes), but have been underutilized for whole-cell therapies.
  • Proof-of-concept demonstrated successful expansion of: 
    • Human induced pluripotent stem cells (iPSCs) in a 50 mL MiniTide® 3D bioreactor. 
    • Mesenchymal stromal cells (MSCs) in a 0.1 L packed-bed bioreactor producing approximately 1–3 billion cells. 
  • Integrated automated closed-system cell harvesting addresses a key bottleneck in fixed-bed bioreactor manufacturing.
  • Offers a scalable, automated, and closed manufacturing platform for allogeneic cell therapies. 
  • Potential to significantly reduce cost of goods (COGs) compared with conventional multilayer cell culture systems.
  • Demonstrates the feasibility of packed-bed bioreactors as a next-generation manufacturing platform for large-scale stem cell therapy production.
View Website

Speakers

  • Johnny Zhuang, Director of Sales and Application, EXODUS BIO, USA

Session Description

Extracellular vesicles (EVs) are increasingly important in cell therapy, regenerative medicine, biomarker discovery, and therapeutic translation. However, EV isolation remains a major workflow bottleneck because many conventional methods are manual, time-consuming, difficult to standardize, or challenging to scale. This session will introduce EXODUS as an automated EV isolation platform designed to improve recovery, purity, reproducibility, and workflow efficiency while maintaining EV integrity and downstream biological activity. Using application examples from biofluid EV isolation, cell culture medium EV preparation, engineered EV regenerative medicine, and large-volume process development, the presentation will show how automated, gentle isolation can support functional readouts and translational decision-making. The session will also discuss how the EXODUS platform family can support research-scale workflows, multi-channel process screening, and larger-volume EV preparation for cell therapy and regenerative medicine programs.

Session Objectives

  • Understand key EV isolation bottlenecks in cell therapy and regenerative medicine translation.
  • Learn how automated EXODUS workflows improve consistency, purity, recovery, and hands-on efficiency.
  • Review application examples across biofluid EVs, cell culture EVs, engineered EVs, and functional EV readouts.
View Website

Speakers

  • Isaac Chen, Channel Manager – SEA + Korea, Lonza Bioscience Singapore Pte Ltd., Singapore

Session Description

The 4D-Nucleofector® LV Unit PRO is the new generation advanced electroporation platform enabling efficient, non-viral delivery of complex cargos for scalable T cell engineering and cell therapy manufacturing. Built on established Nucleofector® technology, the system supports versatile transfection of DNA, mRNA, and CRISPR-based components with high efficiency and cell viability. Process conditions developed at small scale are seamlessly translated to large volumes, allowing reliable modification of up to 1 × 10⁹ cells using fixed-volume and flow-through cartridge formats. Robust performance is demonstrated across multiple donors, cargo types, and applications, including gene knockout, knock-in, and transposon-based integration, while maintaining stable editing efficiency, high cell recovery (>95%), and strong expansion capacity. The platform also supports closed, GMP-compatible workflows with validated consumables and compliant software, facilitating transition from research to manufacturing. Overall, LV Unit PRO provides a scalable, reproducible, and regulatory-aligned solution for non-viral cell and gene therapy production.

Session Objectives

  • Non-viral technologies are now viable alternatives to viral methods for cell therapy manufacturing - delivering clinically relevant cargos efficiently while reducing complexity and risk.
  • LV Unit PRO maintains efficiency, viability, and reproducibility from R&D to large-scale manufacturing.
  • Strong strategic fit for cell therapy manufacturing by providing a reliable, flexible, and regulatory-aligned solution for commercial-scale production.
View Website

Speakers

  • Li Yen Mah, Technical Sales Manager (APAC), ACROBiosystems, Malaysia

Session Description

Cell and gene therapies are redefining modern medicine, demanding precision and reliability at every manufacturing stage. Unlike traditional biologics, these living therapies leave no room for error. Every reagent decision directly impacts patient outcomes. To address this, we have developed a comprehensive portfolio spanning the full CGT continuum — from GMP-grade cytokines and CAR target proteins to validated cell line models and recombinant factor C endotoxin detection. This end-to-end offering enables researchers and manufacturers to meet evolving regulatory expectations with confidence. Purpose-built for the complexity of CGT matrices and workflows, these solutions accelerate IND timelines, strengthen lot release decisions, and bridge the gap between cutting-edge research and the safe delivery of life-changing therapies.

Session Objectives

  • Recap of CGT challenges 
  • Qualities of a GMP facility and beyond 
  • Fit-for-purpose tools at every stage
  • Choosing the right QC solutions  
View Website

Speakers

  • Dr. Paula Lam, Chief Scientific Officer, BioCell Innovations Pte. Ltd., Singapore

Session Description

Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable clinical efficacy in hematologic malignancies; however, challenges remained including limited CAR persistence, antigen escape, manufacturing complexity, high production cost and treatment-associated toxicities. Emerging advances in synthetic biology, cellular engineering, and bioprocess development are creating new opportunities to overcome these limitations and redefine the next generation of adoptive cell therapies. In this presentation, BioCell Innovations will present its integrated strategy that combines rational CAR engineering with advanced and scalable manufacturing technologies to optimize therapeutic performance outputs.

Session Objectives

  • Addressing critical CAR-T manufacturing bottlenecks through integrated process innovation.
View Website

Speakers

  • Dr. Ann Koay, MSAT Lead, CellVec Pte Ltd., Singapore

Session Description

The rapid growth of CAR-T therapies and clinical trials has increased demand for high-quality lentiviral vectors (LVVs) across all stages of development. Early-phase studies require flexible small-batch GMP production, while late-stage programs demand scalable, high-volume supply. CellVec is addressing these challenges through the development of robust and scalable LVV manufacturing platforms. This presentation will highlight key considerations in balancing early clinical supply with long-term scalability, and discuss strategies to improve process robustness, reproducibility, and GMP readiness. Experience from CellVec’s LVV manufacturing platform across multiple CAR transgenes will be shared to illustrate key technical challenges and practical hurdles encountered in process development and manufacturing.

Session Objectives

  • Flexible, scalable manufacturing platforms are essential to bridge small-batch clinical needs and commercial-scale requirements.
  • Process robustness and reproducibility are critical to ensuring reliable GMP vector supply.
  • Practical manufacturing experience highlights key technical hurdles in translating LVV processes across diverse CAR constructs.
View Website

Speakers

  • Guo Xiao Liang, CTO of Cellbri, Shenzhen Cellbri Bio-Innovation Technology Co.,Ltd, China

Session Description

CELLBRI is a global leader in intelligent manufacturing infrastructure and new productivity for the cell therapy industry. As the world’s top 3 and China’s exclusive fully integrated tool platform, its products and technologies have been validated by commercial cell drugs and leading pharmaceutical firms. Boasting robust independent R&D strength, over 400 global patents and a comprehensive product lineup, the company delivers full-process automated solutions covering cell separation, culture, formulation and more. Its technologies drastically cut production costs and support over 100 clinical and commercial pipelines worldwide. With facilities across Shenzhen, Beijing and Changzhou and business presence in over 10 countries, CELLBRI advances cell therapy industrialization, addresses affordability challenges and drives the high-quality development of the global cell industry.

Session Objectives

  • Learn about the industry landscape, policy trends and cost breakthroughs driving the rapid growth of global cell therapy.
  • Grasp CELLBRI’s full-stack automated tool platforms and core technologies for cell manufacturing.
  • Understand how innovative solutions slash production costs and boost scalability for cell drug development.
  • Explore the company’s product portfolio, global layout and successful cooperation with leading pharmaceutical partners.
  • Gain insights into future development directions and commercial prospects of the cell therapy sector.
View Website

Speakers

  • Coming Soon

Session Description

Coming Soon
View Website

Speakers

  • Michael Wu, Vice President of Tofflon Advanced Research Institute for Cell and Gene Therapy, Tofflon Group, China

Session Description

Cell and gene therapy (CGT) is at a pivotal stage of transitioning from laboratory research to industrial-scale production. However, challenges such as process scale-up, cost control, supply chain stability, and cross-border regulatory compliance remain critical bottlenecks limiting the global accessibility of innovative therapies. Grounded in Tofflon’s full-industry-chain capabilities, this topic systematically explores efficient CGT industrialization pathways across four key dimensions—engineering, equipment, reagents, and consumables—centered around the three core objectives of “rapid factory construction, rapid production launch, and rapid application.” Leveraging over three decades of deep expertise in the pharmaceutical equipment sector, Tofflon provides customers with comprehensive engineering design and process solutions spanning from R&D pilot-scale to commercial manufacturing, covering a complete supply system that includes core pharmaceutical equipment, critical production reagents, and single-use consumables. Notably, Tofflon has established a robust overseas service network, offering one-stop support for cross-border technology transfer, domestic and international regulatory alignment, overseas facility setup, and localized operational guidance. This enables Chinese CGT innovations to reach global markets while simultaneously bringing international advanced process concepts into China. This topic aims to provide CGT practitioners with an actionable roadmap from bench to mass production, accelerating the safe, compliant, and efficient delivery of innovative therapies to patients worldwide.

Session Objectives

  • Understand Tofflon's systematic capabilities across engineering, equipment, reagents, and consumables
  • Learn how modular factory solutions shorten construction timelines and enable scalable capacity investment
  • Explore ways to accelerate the full journey from lab to commercial manufacturing through integrated services
  • Gain insights into Tofflon's one-stop overseas technology transfer and global deployment support
  • Develop initial ideas for your own project industrialization
View Website

Speakers

  • Ryan Tay, PhD, Commercial Lead APAC, Cell Signaling Technology

Session Description

Chimeric Antigen Receptor (CAR)-T cell therapy is a highly innovative form of immunotherapy that has proven to be successful in treating hematologic malignancies.  As this therapeutic modality continues to evolve toward the targeting of novel combinations of tumor antigens and the development of more efficacious CAR-T cells, there is a need for tools that can be leveraged to selectively manipulate CAR-T cells in preclinical research workflows. Here, we report on a novel and highly versatile recombinant monoclonal antibody raised against the Gly4Ser (G4S) peptide linker, which is commonly integrated into single-chain variable fragment (scFv)-based CARs.  Our data demonstrate the utility of an anti-G4S linker monoclonal antibody for the isolation of CAR T cells, which eliminates the need for a co-expressed marker for selection.  Furthermore, this antibody can be leveraged in flow cytometry assays to provide a direct measure of the surface expression of G4S-linker-containing CARs, independent of CAR specificity.  The versatile attributes of the anti-G4S linker monoclonal antibody warrant further investigation aimed at the development of more standardized CAR-T workflows, thereby eliminating custom reagent development across multiple programs with unique CAR designs.

Session Objectives

  • The anti-G4S antibody represents a platform-enabling tool for CAR-T workflows rather than a program-specific reagent. 
  • Adoption of this strategy can streamline the development of CAR-T therapies, reducing variability and operational burden. 
  • Development of GMP-grade antibody conjugates supports standardized, regulatory-compliant processes for cell therapy production. 
  • This approach eliminates custom reagent development for each new CAR construct, saving time and cost. 
  • Broad applicability across CAR designs positions this tool as a scalable solution for next-generation and multiplexed CAR-T therapies.
View Website

Speakers

  • Lee Chee Yang, Ph.D., Senior Field Application Scientist, Diagnostics and Genomics Group, South Asia Pacific, Agilent Technologies Singapore (Sales) Pte Ltd
  • Federica Tomay, PhD, Field Application Scientist, South Asia Pacific, APAC Technical Specialization & Solutions

Session Description

Cell and gene therapy (CGT) development demands workflows that enable rapid discovery, robust process development, and reliable analytical characterization. In this session, Agilent will showcase its comprehensive portfolio of cell biology and genomics solutions designed to support researchers and biopharma innovators across the CGT continuum. From advanced cellular imaging, automation, and sample preparation to next-generation sequencing, genomics analysis, and quality control workflows, Agilent’s technologies help accelerate research while improving data confidence and reproducibility.

The session will also feature Agilent’s latest product launches and innovations aimed at addressing emerging challenges in CGT, including higher-throughput workflows, enhanced cellular characterization, and streamlined genomic analysis.

Session Objectives

  • Understand current trends and challenges shaping the Cell & Gene Therapy landscape. 
  • Explore Agilent's  Cell Biology and Genomics portfolio for CGT research and development. 
  • Learn how advanced cellular imaging, automation, genomics, and molecular analysis technologies support CGT workflows. 
  • Gain insights into recent Agilent product launches and innovations relevant to cell and gene therapy applications. 
  • Explore opportunities for implementing scalable solutions from discovery through manufacturing support. 
  • Engage with Agilent experts to discuss emerging applications and future directions in CGT research.
View Website